WASHINGTON (Reuters) - Excessive sedation is a “serious safety concern” with an experimental, long-acting form of Eli Lilly and Co’s blockbuster Zyprexa schizophrenia drug, U.S. drug reviewers said in an analysis released on Monday. Food and Drug Administration staff said the injectable formulation, called Zyprexa Adhera, was shown to be effective for acute and long-term treatment of schizophrenia.
